Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Teva Pharmaceutical Industries Limited

< Previous 1 2 3 4 5 Next >
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers ALVO TEVA
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present at the 2024 Bank of America Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers ALVO TEVA
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers ALVO TEVA
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers CG TEVA
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers ALVO TEVA
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reports Growth in Fourth Quarter and Full Year 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.